Alexander Philipovskiy MD, PhD joins Florida Cancer Specialists Drug Development Unit in Lake Mary Florida

Press Release

In Partnership With:

Partner | Oncology Network Providers | <b>Florida Cancer Specialists</b>

Florida Cancer Specialists & Research Institute, LLC (FCS) is pleased to welcome Alexander Philipovskiy, MD, PhD, as a principal investigator at the FCS Drug Development Unit.

Florida Cancer Specialists & Research Institute, LLC (FCS) is pleased to welcome Alexander Philipovskiy, MD, PhD as a principal investigator at the FCS Drug Development Unit in Lake Mary, FL, located at 805 Currency Circle, which is part of Sarah Cannon.

After receiving his medical degree with honors, Dr. Philipovskiy earned a doctorate in Medical Immunology and Microbiology from Odessa State Medical University in Odessa, Ukraine, where he also received residency training in Internal Medicine. He completed a second residency in Internal Medicine at New York Medical College in New York, NY and a fellowship in Medical Oncology & Hematology at New York Medical College Westchester Medical Center in Valhalla, NY. He has been practicing medical oncology and hematology for the past five years with clinical investigator experience, particularly in breast cancer.

“Dr. Philipovskiy has extensive training and experience in oncology research,” said FCS Chief Executive Officer Nathan H. Walcker. “He will enable us to further expand access to cutting-edge Phase 1 clinical trial opportunities for patients in central Florida.”

FCS President & Managing Physician Michael Diaz, MD added, “Dr. Philipovskiy is an outstanding addition to our research team. Our three early phase trial Drug Development Units located in Lake Mary, Lake Nona and Sarasota are serving patients who vitally need advanced treatment options and contributing to ongoing discoveries in cancer diagnosis and treatment.”

“Dr. Philipovskiy will make a generous contribution to our drug development team. His background, interests, and motivation will serve him well. Our Lake Mary DDU has been open and enrolling to clinical trials for 2 years. It is an honor to have him join our talented team,” remarked FCS Director of Drug Development Manish R. Patel, MD.

As a strategic research site for Sarah Cannon, one of the leading clinical research organizations in the world, FCS conducts clinical trials at more than 36 locations throughout the state, with more than 100 Phase 1 trials underway each year.

About Florida Cancer Specialists & Research Institute, LLC: (FLCancer.com)

Recognized by the American Society of Clinical Oncology (ASCO) with a national Clinical Trials Participation Award, Florida Cancer Specialists & Research Institute (FCS) offers patients access to more clinical trials than any private oncology practice in Florida. The majority of new cancer drugs recently approved for use in the U.S. were studied in clinical trials with Florida Cancer Specialists participation (prior to approval). Trained in prestigious medical schools and research institutes, our physicians are consistently ranked nationally as Top Doctors by U.S. News & World Report.

Founded in 1984, Florida Cancer Specialists has built a national reputation for excellence that is reflected in exceptional and compassionate patient care, driven by innovative clinical research, cutting-edge technologies and advanced treatments, including targeted therapies, genomic-based treatment, and immunotherapy. Our highest values are embodied by our outstanding team of highly trained and dedicated physicians, clinicians and staff.